Multiple variant databases are creating competition among groups that disagree on how to advance the most scientifically robust and sustainable sharing model.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
Co-discoverers of the link between the gene EIF2AK4 and specific types of pulmonary hypertension, Intermountain and ARUP are now collaborating to offer clinical testing.
The DTWG proposal for regulating in vitro clinical tests has made it into draft legislation but it still needs support from key stakeholders in the life sciences field.
ARUP's database is one of many options that researchers and oncologists can use to learn about whether alterations in BRCA genes are associated with hereditary breast and ovarian cancer risk.
